A preoperative serum signature of CEA+/CA125+/ CA19-9≥1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer

Liang Liu, Huaxiang Xu, Wenquan Wang, Chuntao Wu, Yong Chen, Jingxuan Yang, Putao Cen, Jin Xu, Chen Liu, Jiang Long, Sushovan Guha, Deliang Fu, Quanxing Ni, Aminah Jatoi, Suresh Chari, Angela L. McCleary-Wheeler, Martin E. Fernandez-Zapico, Min Li, Xianjun Yu

Research output: Contribution to journalArticle

54 Scopus citations

Abstract

Pancreatectomy is associated with significant morbidity and unpredictable outcome, with few diagnostic tools to determine, which patients gain the most benefit from this treatment, especially before the operation. This study aimed to define a preoperative signature panel of serum markers to indicate response to pancreatectomy for pancreatic cancer. Over 1000 patients with pancreatic cancer treated at two independent high-volume institutions were included in this study and were divided into three groups, including resected, locally advanced and metastatic. Eight serum tumor markers most commonly used in gastrointestinal cancers were analyzed for patient outcome. Preoperative CA19-9 independently indicated surgical response in pancreatic cancer. Patients with CA19-9 ≥1000 U/mL generally had a poor surgical benefit. However, a subset of these patients still achieved a survival advantage when CA19-9 levels decreased postoperatively. CEA and CA125 in the presence of CA19-9 ≥1000 U/mL could independently predict the non-decrease of CA19-9 postoperatively. The combination of the three markers was useful for predicting a worse surgical outcome with a median survival of 5.1 months vs. 23.0 months (p < 0.001) for the training cohort and 7.0 months vs. 18.2 months (p < 0.001) for the validation cohort and also suggested a higher prevalence Cancer Therapy of early distant metastasis after surgery. Resected patients with this proposed signature showed no survival advantage over patients in the locally advanced group who did not receive pancreatectomy. Therefore, a preoperative serum signature of CEA+/CA125+/CA19-9 ≥1000 U/mL is associated with poor surgical outcome and can be used to select appropriate patients with pancreatic cancer for pancreatectomy.

Original languageEnglish (US)
Pages (from-to)2216-2227
Number of pages12
JournalInternational Journal of Cancer
Volume136
Issue number9
DOIs
StatePublished - May 1 2015

    Fingerprint

Keywords

  • Pancreatic cancer
  • Predictive potency
  • Serum signature
  • Surgical outcome

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Liu, L., Xu, H., Wang, W., Wu, C., Chen, Y., Yang, J., Cen, P., Xu, J., Liu, C., Long, J., Guha, S., Fu, D., Ni, Q., Jatoi, A., Chari, S., McCleary-Wheeler, A. L., Fernandez-Zapico, M. E., Li, M., & Yu, X. (2015). A preoperative serum signature of CEA+/CA125+/ CA19-9≥1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. International Journal of Cancer, 136(9), 2216-2227. https://doi.org/10.1002/ijc.29242